Trial Profile
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; Heart failure; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPA-REIN
- 29 Jul 2019 Status changed from recruiting to completed.
- 25 May 2018 Trial design published in the Advances in Therapy.
- 31 Mar 2017 New trial record